The growing number of US Food and Drug Administration-approved therapies for acute myeloid leukemia (AML) makes it essential to establish each patient’s prognosis through comprehensive evaluation of patient-specific variables including tumor morphology, cytogenetics, and molecular profile, as well as patient age, performance status, and comorbidities. Improving treatment outcomes in individual patients with AML requires selection of the most appropriate AML therapy based on prognosis, and the recognition and prompt management of adverse drug reactions to help maintain treatment adherence.
Case studies with interactive benchmarking
To improve treatment outcomes in individual patients with AML by comprehensively evaluating prognosis, selecting the most appropriate therapy, and helping maintain adherence by closely monitoring patients during the phases of treatment.
After completing this activity, participants should be better able to:
- Describe recommended diagnostic testing for risk stratification in AML and the implications of testing results on prognosis and treatment
- Devise individualized treatment strategies for patients with AML according to guidelines, clinical trial evidence, risk stratification/molecular testing, and patient preferences
- Identify treatment toxicities associated with novel and emerging therapies in AML and the appropriate steps to manage them and promote patient adherence
Oncology NPs, PAs, and nurses
CNE Credit Designation Statement
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
PA Planner: Jessica Garner, MMS, PA-C
AAPA Credit Designation Statement
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until December 21, 2019. PAs should only claim credit commensurate with the extent of their participation.
This program was planned in accordance with AAPA CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This activity is supported by an educational grant from Celgene Corporation.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Johnson has no relevant financial relationships to disclose.
The Planning Committee for this activity included Jessica Garner, MMS, PA-C of the University of the Pacific and Ruth Cohen and Klara Czbor of Continuing Education Alliance. The members of the Planning Committee have no relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the activity in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: December 28, 2018
Expiration date: December 28, 2019
© 2019 Practicing Clinicians Exchange. All Rights Reserved. CGPCE95018